Global Imaging Network RadMD operates a global imaging network with support sites in over 80 countries and a large pool of 300+ radiologists, indicating strong capacity for multinational clinical trials and scalable service offerings suitable for pharma and biotech partners expanding internationally.

Therapeutic Focus Specialization in oncology and wide range of therapeutic areas positions RadMD as a versatile iCRO partner for oncology programs and cross-therapy trials, presenting opportunities to upsell imaging strategy, centralized reads, and reader training to new and existing clients.

Full-Service iCRO Comprehensive service suite from imaging strategy and regulatory consulting to data management and rescue study support enables RadMD to act as a one-stop shop, reducing outsourcing friction and creating multi-service cross-sell opportunities with current customers.

Strategic Partnerships Past collaborations and European expansion demonstrate a willingness to grow through partnerships; engaging with EU/regional pharma, CROs, and device firms could unlock co-development imaging programs and CME-aligned training offerings for broader market reach.

Growth Indicators Revenue in the mid five-figure to mid six-figure range and a mid-sized team imply agility and cost-effective operations; this suggests targeting mid-market biotech and mid-cap pharma with compelling ROI cases for expanding imaging endpoints and centralized review services.